Brief: Egetis Therapeutics Secures Approx. Sek 462 Mln In Combined Financing Comprising

Egetis Therapeutics AB (publ)

11/10/2023 09:24

Oct 11 (Reuters) - Egetis Therapeutics Ab
(Publ) EGTX.ST :
    * SAID ON TUESDAY: EGETIS THERAPEUTICS AB (PUBL), TODAY
ANNOUNCED
THAT IT HAS OBTAINED COMMITTED FINANCING IN THE FORM OF AN
ISSUANCE OF 42,982,331 NEW SHARES 
    * AT A SUBSCRIPTION PRICE OF SEK 4.00 PER SHARE 
    * THROUGH WHICH THE COMPANY RECEIVES GROSS PROCEEDS OF
APPROXIMATELY SEK 172 MILLION, BEFORE TRANSACTION COSTS
    * INTER ALIA LED AND SUBSCRIBED FOR BY US HEALTHCARE
INVESTOR
FRAZIER LIFE SCIENCES AND CONCURRENTLY WITH A DEBT FINANCING OF
UP TO EUR 25 MILLION (CORRESPONDING TO APPROXIMATELY SEK 290
MILLION) FROM BLACKROCK (FORMERLY KREOS) 

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN3Pn4Q5
 Further company coverage:  EGTX.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))